NEW YORK (GenomeWeb News) – MDS today lowered its revenue guidance for fiscal year 2008, one week before it will report results, to a range of $1.21 billion to $1.22 billion from its previous expectations of $1.23 billion to $1.25 billion.
 
The Toronto-based firm also lowered its expected adjusted EBITDA to a range of between $148 million and $154 million from a range of between $160 million and $170 million for the fiscal year, which ended Oct. 31.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.